Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23,792 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma.
Armstrong AJ, Nixon AB, Carmack A, Yang Q, Eisen T, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, George DJ, Halabi S. Armstrong AJ, et al. Among authors: yang q. Clin Cancer Res. 2021 Jun 15;27(12):3503. doi: 10.1158/1078-0432.CCR-21-1636. Clin Cancer Res. 2021. PMID: 34117029 No abstract available.
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
Armstrong AJ, Nixon AB, Carmack A, Yang Q, Eisen T, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, George DJ, Halabi S. Armstrong AJ, et al. Among authors: yang q. Clin Cancer Res. 2021 Jun 15;27(12):3317-3328. doi: 10.1158/1078-0432.CCR-20-4504. Epub 2021 Feb 16. Clin Cancer Res. 2021. PMID: 33593885 Free article. Clinical Trial.
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.
Brown LC, Halabi S, Schonhoft JD, Yang Q, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Barnett ES, Carbone EA, Zhao JL, Healy P, Anand M, Gill A, Jendrisak A, Berry WR, Gupta S, Gregory SG, Wenstrup R, Antonarakis ES, George DJ, Scher HI, Armstrong AJ. Brown LC, et al. Among authors: yang q. Clin Cancer Res. 2021 Jul 15;27(14):4077-4088. doi: 10.1158/1078-0432.CCR-20-3471. Epub 2021 Apr 5. Clin Cancer Res. 2021. PMID: 33820782 Free PMC article.
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial.
Halabi S, Yang Q, Carmack A, Zhang S, Foo WC, Eisen T, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, George DJ, Armstrong AJ. Halabi S, et al. Among authors: yang q. Kidney Cancer J. 2021 Oct;19(3):64-72. doi: 10.52733/kcj19n3-a1. Kidney Cancer J. 2021. PMID: 34765076 Free PMC article.
PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer.
Gupta S, Halabi S, Yang Q, Roy A, Tubbs A, Gore Y, George DJ, Nanus DM, Antonarakis ES, Danila DC, Szmulewitz RZ, Wenstrup R, Armstrong AJ. Gupta S, et al. Among authors: yang q. Clin Cancer Res. 2023 May 15;29(10):1929-1937. doi: 10.1158/1078-0432.CCR-22-3233. Clin Cancer Res. 2023. PMID: 36897758 Free PMC article.
Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab.
Nixon AB, Liu Y, Yang Q, Luo B, Starr MD, Brady JC, Kelly WK, Beltran H, Morris MJ, George DJ, Armstrong AJ, Halabi S. Nixon AB, et al. Among authors: yang q. Prostate Cancer Prostatic Dis. 2024 Feb 12. doi: 10.1038/s41391-024-00794-3. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38347114
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
Scher HI, Armstrong AJ, Schonhoft JD, Gill A, Zhao JL, Barnett E, Carbone E, Lu J, Antonarakis ES, Luo J, Tagawa S, Dos Anjos CH, Yang Q, George D, Szmulewitz R, Danila DC, Wenstrup R, Gonen M, Halabi S. Scher HI, et al. Among authors: yang q. Eur J Cancer. 2021 Jun;150:83-94. doi: 10.1016/j.ejca.2021.02.042. Epub 2021 Apr 21. Eur J Cancer. 2021. PMID: 33894633 Free PMC article.
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Halabi S, Yang Q, Roy A, Luo B, Araujo JC, Logothetis C, Sternberg CN, Armstrong AJ, Carducci MA, Chi KN, de Bono JS, Petrylak DP, Fizazi K, Higano CS, Morris MJ, Rathkopf DE, Saad F, Ryan CJ, Small EJ, Kelly WK. Halabi S, et al. Among authors: yang q. J Clin Oncol. 2023 May 20;41(15):2736-2746. doi: 10.1200/JCO.22.02661. Epub 2023 Apr 11. J Clin Oncol. 2023. PMID: 37040594 Free PMC article.
23,792 results
You have reached the last available page of results. Please see the User Guide for more information.